Swedish clinical-stage pharmaceutical company Vicore Pharma Holding AB (STO:VICO) announced on Wednesday that the US Food and Drug Administration (FDA) has granted Fast Track designation to its lead candidate, buloxibutid, for the treatment of idiopathic pulmonary fibrosis (IPF).
Buloxibutid, a first-in-class AT2 receptor agonist, has the potential to modify the disease progression of IPF by promoting alveolar repair and resolving fibrosis.
Fast Track designation aims to expedite the development of drugs for serious or life-threatening conditions. Vicore plans to leverage this designation to expedite the development and potential approval of buloxibutid.
The Phase 2b ASPIRE trial evaluating the safety and efficacy of buloxibutid in IPF patients is currently enrolling.
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
HeartBeam submits FDA 510(k) application for groundbreaking 12-lead ECG synthesis software
FDA grants Vicore Pharma Fast Track Designation for buloxibutid in idiopathic pulmonary fibrosis
FDA accepts Saol Therapeutics' SL1009 New Drug Application for Priority Review
FDA grants Regenerative Medicine Advanced Therapy designation to Beacon Therapeutics' laru-zova
AstraZeneca and Daiichi Sankyo's Enhertu approved in US for earlier treatment of breast cancer
ImmunityBio's ANKTIVA receives EMA review for BCG-unresponsive bladder cancer treatment
ColdVentures partners with Medco Sports Medicine to combat heat stroke
eNeura Inc expands access to innovative migraine treatment
Norgine and X4 advance mavorixafor approval in Europe
Median Technologies secures funding for eyonis Lung Cancer Screening software
Genprex commences Phase 2 expansion of Acclaim-3 clinical study in ES-SCLC
Biogen submits applications for higher dose regimen of nusinersen in SMA